Nisa Investment Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Nisa Investment Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.9K	Hold	892	–	–	﹤0.01%	2623
2025 Q4	$2.17K	Hold	892	–	–	﹤0.01%	2598
2025 Q3	$3.38K	Hold	892	–	–	﹤0.01%	2519
2025 Q2	$2.21K	Buy	+892	New	+$1.72K	﹤0.01%	2580
2025 Q1	–	Sell	-300	Closed	-$642	–	2996
2024 Q4	$642	Buy	300 +229	+323%	+$656	﹤0.01%	2775
2024 Q3	$309	Buy	+71	New	+$386	﹤0.01%	2798
2021 Q3	–	Sell	-4,200	Closed	-$51	–	2305
2021 Q2	$51	Buy	+4,200	New	+$83K	﹤0.01%	1934

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Nisa Investment Advisors's BDTX Position: Q1 2026 in Review

Nisa Investment Advisors held its Black Diamond Therapeutics (BDTX) position steady in Q1 2026 at 892 shares worth $1.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

Nisa Investment Advisors first reported a position in BDTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $3.38K in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Nisa Investment Advisors held 892 shares of Black Diamond Therapeutics worth $1.9K as of Q1 2026.
Nisa Investment Advisors left its Black Diamond Therapeutics share count unchanged in Q1 2026.
Black Diamond Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2623 holding.
Nisa Investment Advisors first reported a position in Black Diamond Therapeutics in Q2 2021 and has held it in 7 quarters since.
Nisa Investment Advisors's Black Diamond Therapeutics position peaked at $3.38K in Q3 2025.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.